Because LAR would require less frequent injections--perhaps twice a month--Kliff believes this version to be the real blockbuster in Amylin's pipeline.
If a patient developed pancreatitis while taking Byetta LAR, "there would be no way to turn the effects of the drug off, which could lead to a substantially worse outcome, " Anderson wrote.